ATE309202T1 - N-BIPHENYL METHYL AMINO CYCLO ALKANE CARBOXYLIC ACID AMIDE DERIVATIVES WITH A SUBSTITUENT ON THE METHYL GROUP SUITABLE AS BRADYKININ ANTAGONISTS - Google Patents

N-BIPHENYL METHYL AMINO CYCLO ALKANE CARBOXYLIC ACID AMIDE DERIVATIVES WITH A SUBSTITUENT ON THE METHYL GROUP SUITABLE AS BRADYKININ ANTAGONISTS

Info

Publication number
ATE309202T1
ATE309202T1 AT03737624T AT03737624T ATE309202T1 AT E309202 T1 ATE309202 T1 AT E309202T1 AT 03737624 T AT03737624 T AT 03737624T AT 03737624 T AT03737624 T AT 03737624T AT E309202 T1 ATE309202 T1 AT E309202T1
Authority
AT
Austria
Prior art keywords
substituent
carboxylic acid
acid amide
amide derivatives
group suitable
Prior art date
Application number
AT03737624T
Other languages
German (de)
Inventor
Michael R Wood
Neville J Anthony
Mark G Bock
Dong-Mei Feng
Scott D Kuduk
Dai-Shi Su
Jenny Miu-Chun Wai
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE309202T1 publication Critical patent/ATE309202T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
AT03737624T 2002-02-08 2003-02-04 N-BIPHENYL METHYL AMINO CYCLO ALKANE CARBOXYLIC ACID AMIDE DERIVATIVES WITH A SUBSTITUENT ON THE METHYL GROUP SUITABLE AS BRADYKININ ANTAGONISTS ATE309202T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35506202P 2002-02-08 2002-02-08
US41017202P 2002-09-12 2002-09-12
PCT/US2003/003338 WO2003066577A1 (en) 2002-02-08 2003-02-04 N-biphenylmethyl aminocycloalkanecarboxamide derivatives with a substiituent on the methyl useful as bradykinin antagonists

Publications (1)

Publication Number Publication Date
ATE309202T1 true ATE309202T1 (en) 2005-11-15

Family

ID=27737481

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03737624T ATE309202T1 (en) 2002-02-08 2003-02-04 N-BIPHENYL METHYL AMINO CYCLO ALKANE CARBOXYLIC ACID AMIDE DERIVATIVES WITH A SUBSTITUENT ON THE METHYL GROUP SUITABLE AS BRADYKININ ANTAGONISTS

Country Status (27)

Country Link
US (2) US6919343B2 (en)
EP (1) EP1501787B1 (en)
JP (1) JP4098249B2 (en)
KR (1) KR20040083440A (en)
CN (1) CN1328247C (en)
AR (1) AR038377A1 (en)
AT (1) ATE309202T1 (en)
AU (1) AU2003216169B2 (en)
BR (1) BR0307508A (en)
CA (1) CA2474373C (en)
DE (1) DE60302240T2 (en)
DK (1) DK1501787T3 (en)
EA (1) EA007297B1 (en)
EC (1) ECSP045217A (en)
ES (1) ES2250899T3 (en)
HR (1) HRP20040677A2 (en)
IS (1) IS7372A (en)
JO (1) JO2356B1 (en)
MA (1) MA27108A1 (en)
MX (1) MXPA04007660A (en)
NO (1) NO20043739L (en)
NZ (1) NZ534062A (en)
PE (1) PE20030986A1 (en)
PL (1) PL371664A1 (en)
RS (1) RS65404A (en)
TW (1) TWI259079B (en)
WO (1) WO2003066577A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507753B2 (en) * 2001-12-28 2009-03-24 Takeda Chemical Industries Ltd. Biaryl compound and use thereof
ES2256727T3 (en) * 2002-02-08 2006-07-16 MERCK & CO., INC. DERIVATIVES OF N-BIFENYLMETIL AMINOCICLOALCANOCARBOXAMIDA.
CA2495914A1 (en) * 2002-08-29 2004-03-11 Merck & Co., Inc. N-biarylmethyl aminocycloalkanecarboxamide derivatives
US20070093485A1 (en) * 2002-12-19 2007-04-26 Elan Pharmaceuticals, Inc. Substituted n-phenyl sulfonamide bradykinin antagonists
JP2007501790A (en) * 2003-08-07 2007-02-01 メルク　エンド　カムパニー　インコーポレーテッド Sulfonyl-substituted N- (biarylmethyl) aminocyclopropanecarboxamide
WO2005063690A1 (en) * 2003-12-22 2005-07-14 Merck & Co., Inc. Alpha-hydroxy amides as bradykinin antagonists or inverse agonists
CA2557858A1 (en) * 2004-03-02 2005-09-15 Merck & Co., Inc. Amino cyclopropane carboxamide derivatives as bradykinin antagonists
US20050245543A1 (en) * 2004-04-30 2005-11-03 Pfizer Inc Histamine-3 receptor antagonists
CA2575706A1 (en) * 2004-08-02 2006-02-23 Bebaas, Inc. Vitamin b12 compositions
DE102004060542A1 (en) * 2004-12-16 2006-07-06 Sanofi-Aventis Deutschland Gmbh Hydroxybiphenyl carboxylic acids and derivatives, process for their preparation and their use
EP1830869B1 (en) 2004-12-24 2013-05-22 Spinifex Pharmaceuticals Pty Ltd Method of treatment or prophylaxis
US20070178141A1 (en) * 2005-09-07 2007-08-02 Bebaas, Inc. Vitamin B12 compositions
US20130131007A1 (en) 2005-09-07 2013-05-23 Bebaas, Inc. Vitamin b12 compositions
CA2866540A1 (en) * 2006-03-20 2007-09-27 Spinifex Pharmaceuticals Pty Ltd. Method of treatment or prophylaxis of inflammatory pain
US8945505B2 (en) 2007-02-02 2015-02-03 Panaphix, Inc. Use of arsenic compounds for treatment of pain and inflammation
JP4827986B2 (en) 2007-06-08 2011-11-30 マンカインド コーポレ−ション IRE-1α inhibitor
CA2697946C (en) * 2007-08-29 2016-06-28 Boehringer Ingelheim International Gmbh Bradykinin b1-antagonists
US20090270394A1 (en) * 2008-04-28 2009-10-29 Galemmo Jr Robert Cyclylamine derivatives as calcium channel blockers
WO2010097373A1 (en) * 2009-02-26 2010-09-02 Boehringer Ingelheim International Gmbh Compounds for use as bradykinin b1 antagonists
NZ594674A (en) * 2009-02-26 2013-12-20 Boehringer Ingelheim Int Compounds as bradykinin b1 antagonists
WO2010097374A1 (en) * 2009-02-26 2010-09-02 Boehringer Ingelheim International Gmbh Compounds for use as bradykinin b1 antagonists
EP2539323B3 (en) * 2010-02-23 2017-10-04 Boehringer Ingelheim International GmbH Compounds as bradykinin B1 antagonists
US10457810B2 (en) 2009-08-24 2019-10-29 Board Of Trustees Of Michigan State University Densified biomass products containing pretreated biomass fibers
BR112012026710B8 (en) 2010-04-19 2020-06-23 Univ Michigan State method for producing a product extracted from lignocellulosic biomass and method for producing a product digested from lignocellulosic biomass
US8937073B2 (en) * 2010-08-20 2015-01-20 Boehringer Ingelheim International Gmbh Disubstituted tetrahydrofuranyl compounds and their use as B1-receptor antagonists
HUP1000598A2 (en) * 2010-11-05 2012-09-28 Richter Gedeon Nyrt Indole derivatives
US8912221B2 (en) * 2010-12-27 2014-12-16 Hoffmann-La Roche Inc. Biaryl amide derivatives
US8592426B2 (en) * 2011-01-24 2013-11-26 Hoffmann—La Roche Inc. Aryl-benzocycloalkyl amide derivatives
JP2021501785A (en) * 2017-11-02 2021-01-21 カリコ ライフ サイエンシーズ エルエルシー Modulator of integrated stress pathway
TWI771621B (en) 2018-10-11 2022-07-21 美商嘉來克生命科學有限責任公司 Prodrug modulators of the integrated stress pathway

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270317A (en) * 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
IL99372A0 (en) 1990-09-10 1992-08-18 Ciba Geigy Ag Azacyclic compounds
US5208236A (en) * 1992-09-23 1993-05-04 Schering Corporation N-(acylaminomethyl)glutaryl amino acids and use
DK0655461T3 (en) 1993-11-16 2000-10-02 Novartis Ag Cyclic amino acid derivatives with ACE and NEP inhibitory activity
WO1997011717A1 (en) 1995-09-27 1997-04-03 Novartis Ag Treatment of chronic progressive renal failure
US6433185B1 (en) * 1996-01-11 2002-08-13 Sanofi-Synthelabo N-(arylsulphonyl) amino acid derivatives, process for their preparation and pharmaceutical compositions containing them
FR2743562B1 (en) * 1996-01-11 1998-04-03 Sanofi Sa N- (ARYLSULFONYL) AMINO ACID DERIVATIVES, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
HUP0101640A3 (en) 1998-04-23 2002-10-28 Novartis Ag Certain thoil inhibitors of endothelin-converting enzyme
JP3646062B2 (en) 1998-04-23 2005-05-11 ノバルティス アクチエンゲゼルシャフト Heteroaryl-substituted thiol-type inhibitors of endothelin converting enzyme
US20020052370A1 (en) 2000-07-06 2002-05-02 Barber Christopher Gordon Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase
DE10036121A1 (en) 2000-07-25 2002-02-07 Merck Patent Gmbh N-Substituted-1-amino-1,1-dialkyl-carboxylic acid derivatives
ES2256727T3 (en) 2002-02-08 2006-07-16 MERCK & CO., INC. DERIVATIVES OF N-BIFENYLMETIL AMINOCICLOALCANOCARBOXAMIDA.

Also Published As

Publication number Publication date
MXPA04007660A (en) 2004-11-10
AU2003216169B2 (en) 2008-12-04
TW200302718A (en) 2003-08-16
CA2474373C (en) 2009-05-26
DE60302240T2 (en) 2006-07-13
RS65404A (en) 2007-02-05
MA27108A1 (en) 2004-12-20
CA2474373A1 (en) 2003-08-14
WO2003066577A1 (en) 2003-08-14
EP1501787A1 (en) 2005-02-02
JP4098249B2 (en) 2008-06-11
JO2356B1 (en) 2006-12-12
EA007297B1 (en) 2006-08-25
JP2005517006A (en) 2005-06-09
US20030220375A1 (en) 2003-11-27
TWI259079B (en) 2006-08-01
DK1501787T3 (en) 2006-03-20
BR0307508A (en) 2004-12-07
IS7372A (en) 2004-07-26
DE60302240D1 (en) 2005-12-15
AU2003216169A1 (en) 2003-09-02
ES2250899T3 (en) 2006-04-16
PE20030986A1 (en) 2003-11-19
NZ534062A (en) 2006-06-30
US6919343B2 (en) 2005-07-19
EA200401054A1 (en) 2005-02-24
ECSP045217A (en) 2004-09-28
NO20043739L (en) 2004-10-29
PL371664A1 (en) 2005-06-27
EP1501787B1 (en) 2005-11-09
KR20040083440A (en) 2004-10-01
US20050084463A1 (en) 2005-04-21
HRP20040677A2 (en) 2005-06-30
CN1328247C (en) 2007-07-25
CN1630633A (en) 2005-06-22
AR038377A1 (en) 2005-01-12

Similar Documents

Publication Publication Date Title
ATE309202T1 (en) N-BIPHENYL METHYL AMINO CYCLO ALKANE CARBOXYLIC ACID AMIDE DERIVATIVES WITH A SUBSTITUENT ON THE METHYL GROUP SUITABLE AS BRADYKININ ANTAGONISTS
NO20054958D0 (en) Substituted amino carboxylic acids
ATE461191T1 (en) N-SUBSTITUTED 2-OXODIHYDROPYRIDINE DERIVATIVES AS NPY ANTAGONISTS
DE60335062D1 (en) spray gun
ATE344798T1 (en) INDOLE DERIVATIVES SUITABLE AS HISTAMINE H3 ANTAGONISTS
DE60315420D1 (en) Heterocyclic tripeptides as hepatitis C inhibitors
ATE402921T1 (en) CYCLIC AMINE WITH A HETEROCYCLIC SUBSTITUENT AS BACE-1 INHIBITORS
ATE406361T1 (en) 3-SUBSTITUTED 5,6-DIARYL-PYRAZINE-2-CARBONIC ACID AMIDE AND -2-SULFONIC ACID AMIDE DERIVATIVES AS CB1 MODULATORS
HK1117507A1 (en) Heterocyclic substituted phenyl methanones as inhibitors of the glycine transporter 1
ATE499347T1 (en) AMIDE DERIVATIVES
DE60315862D1 (en) DIHYDROPYRIDINONE DERIVATIVES AS HNE INHIBITORS
DE60110844D1 (en) CHINAZOLONE DERIVATIVES AS ALFA 1A / B ADRENOZEPTOR ANTAGONISTS
ATE496916T1 (en) QUINICLIDINE DERIVATIVES OF (HETERO)ARYLCYCLOHEPTANCARBOXIC ACIDS AS ANTAGONISTS ON THE MUSCARIN RECEPTOR
DE60318890D1 (en) ALMOND ACID DERIVATIVES
ATE392897T1 (en) QUINOLINE DERIVATIVES AS NPY ANTAGONISTS
AP2076A (en) New Heterocyclic carboxylic acid amide derivatives
DE60327407D1 (en) IMMUNOMODULATING PEPTIDES
EA200700659A1 (en) CYCLIZING PEPTIDE
IS7833A (en) Combined heterocyclic compounds
DK1652843T3 (en) amide derivatives
EA200400724A1 (en) METABOLITES (3 - {[(4-TRET-BUTYLBENZYL) - (Pyridine-3-Sulfonyl) AMINO] METHYL} PHENOXY) ACETIC ACID
ATE384530T1 (en) 4-AMINOQUINOLINE-3-CARBONIC ACID AMIDE DERIVATIVES AS PDE4 INHIBITORS
DE602004000960D1 (en) Stud welding equipment
ATE431350T1 (en) AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING EFFECT
ATE309994T1 (en) ALKOXYCARBONYLAMINOBENZOIC ACID OR ALKOXYCARBONYLAMINOTETRAZOLYLPHENYL DERIVATIVES AS IP ANTAGONISTS

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1501787

Country of ref document: EP

REN Ceased due to non-payment of the annual fee
EEFA Change of the company name